A5102911963- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Renal cell carcinoma treatment
- Inflammatory mediators and NSAID effects
- Cancer survivorship and care
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Thyroid Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
CancerCare Manitoba
2012-2024
University of Manitoba
2007-2024
Marqués de Valdecilla University Hospital
2008-2023
Memorial Sloan Kettering Cancer Center
2007-2023
St. Boniface Hospital
2005-2016
SWOG Cancer Research Network
2010-2012
The Barbara Ann Karmanos Cancer Institute
2010-2012
Cancer Research Center
2007-2010
Fred Hutch Cancer Center
2010
Spartanburg Regional Medical Center
2010
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid (FOLFOX4) as first-line therapy in metastatic colorectal cancer. NO16966 was a randomised, two-arm, non-inferiority, phase III comparison of XELOX FOLFOX4, subsequently amended to 2 × factorial design with further randomisation bevacizumab or placebo. A planned follow-up exploratory analysis OS performed. The intent-to-treat (ITT) population...
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high activity in renal cell carcinoma (RCC) and is now widely used for patients with metastatic disease. Although generally well tolerated associated low incidence of common toxicity criteria grade 3 or 4 toxicities, sunitinib exhibits distinct pattern novel side effects that require monitoring management. This article summarizes the most important proposes recommendations their monitoring, prevention...
PURPOSE: The time spent in pursuing treatments for advanced cancer can be substantial. We have previously proposed a pragmatic and patient-centered metric of these costs—which we term toxicity—as any day with physical health care system contact. This includes outpatient visits (eg, bloodwork, scans, etc), emergency department visits, overnight stays facility. Herein, sought to assess toxicity completed randomized controlled trial (RCT). METHODS: conducted secondary analysis the Canadian...
Thyroid cancer management is rapidly changing. The identification of actionable biomarkers through both germline and somatic testing are now an integral part directing patient management. However, deficiencies disparities within existing thyroid biomarker test approaches resulting in inconsistent application for care. An expert panel was convened to create consensus algorithms recommendations on patients diagnosed with medullary cancer, non-anaplastic follicular cell-derived or anaplastic...
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay prevent care providers from being able prescribe optimal therapy. Eighteen Canadian clinicians the medicine, nursing pharmacy professions met develop consensus recommendations defining reasonable performance standards around process...
4030 Background: In a phase II study in untreated MCRC patients, XELOX (capecitabine + oxaliplatin) appeared to have similar efficacy compared with previously published FOLFOX4 data [1]. We therefore started III 2-arm open-label non-inferiority comparing FOLFOX4. 2003 the addition of bevacizumab (Bev) irinotecan/5-FU/LV was shown improve progression-free survival (PFS) and overall [2]. then amended our trial 2x2 partially blinded assess Bev. Methods: Original study: (oxaliplatin 130 mg/m 2...
Abstract Introduction Although contact days—days with health-care outside home—are increasingly adopted as a measure of time toxicity and treatment burden, they could also serve surrogate treatment-related harm. We sought to assess the association between days patient-reported outcomes prognostic ability days. Methods conducted secondary analysis CO.17 that evaluated cetuximab vs supportive care in patients advanced colorectal cancer. collected European Organisation for Research Treatment...
Globally, hepatocellular carcinoma (hcc) is the third most common cause of death from cancer, after lung and stomach cancer. The incidence hcc in Canada increasing expected to continue increase over next decade. Given high mortality rate associated with hcc, steps are required mitigate impact disease. To address this challenging situation, a panel 17 experts, representing gastroenterologists, hepatologists, hepatobiliary surgeons, medical oncologists, pathologists, radiologists across...
Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors. Bevacizumab an anti-VEGF-A monoclonal antibody clinical benefit in previously treated metastatic colorectal cancer (mCRC). Patients mCRC who had progressed following first-line therapy were randomised 1 : to modified (m)FOLFOX6 plus cediranib (20 or 30 mg day−1) bevacizumab (10 kg−1 every 2 weeks). The primary objective was compare progression-free...
Well-differentiated neuroendocrine tumours (nets-previously called "carcinoid tumours") are relatively rare originating from the diffuse system; they found most often in bronchial or gastrointestinal systems. In Canada, gastroenterohepatic NETS represent less than 0.25% of oncology cases. Because relative rarity these tumours, diagnostic and therapeutic approaches vary based on individual physician experience. A number European North American groups have developed consensus guidelines for...
Response assessment in advanced pancreatic cancer (APC) is difficult and predictive markers are needed. There insufficient data on the value of carbohydrate antigen 19–9 (CA 19-9) cytostatic-targeted therapies. Axitinib, a selective vascular endothelial growth factor (VEGF) receptors 1, 2, 3 inhibitor, may increase overall survival (OS) APC. We assessed serum CA 19-9, clinical outcomes diastolic blood pressure (dBP) APC patients receiving gemcitabine plus axitinib (Gem+A) or alone. In total...
Monoclonal antibodies against the epidermal growth factor receptor (anti-egfr) when used in treatment of metastatic colorectal cancer are associated with improved survival. Patients whose tumours harbor a KRAS mutation codon 12 or 13 have been shown not to benefit from anti-egfr antibodies. The importance status management patients has led elaboration Canadian consensus recommendations on testing, aim standardizing practice across Canada and reconciling testing access clinical demand for...
In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement overall survival has considered “gold standard”—the most convincing measure efficacy. However, requires larger patient numbers and longer follow-up may often be confounded by other factors, including subsequent therapies crossover. Given number active for potential investigation, demand rapid evaluation early availability new is growing. Progression-free...
3528 Background: RC and LC differ with respect to biology, pathology, epidemiology. Further, recent SEER data suggests a mortality difference between that varies by stage: stage II III having lower higher mortality, respectively. We examined if the primary tumour site can also predict for outcome in pre-treated, chemotherapy refractory, metastatic colon cancer (MCC). compared vs. as predictor efficacy of EGFR inhibition CET. Methods: Using CO.17 (CET BSC), we coded 399 pts (cecum transverse...
Purpose S0205 was a randomized clinical trial that compared the therapeutic impact of gemcitabine versus plus cetuximab. Study results for patient-reported health-related quality life (HRQL) outcomes are reported. Patients and Methods completed Brief Pain Inventory measure emotional well-being (each measured on 0 to 10 scale) at baseline weeks 5, 9, 13, 17 postrandom assignment. Worst pain status classified as palliated (worst scores < 5 maintained 2 consecutive cycles) or not (remaining...
4551 Background: The current standard of care for patients (pts) with advanced pancreatic cancer (APC) is gemcitabine (GEM)- based chemotherapy. Axitinib (AG) a potent inhibitor vascular endothelial growth factor receptors. A phase I study AG in solid tumors identified 5 mg BID as the therapeutic starting dose. main objectives this trial are to determine whether overall survival (OS) combination and GEM superior that alone first-line therapy pts APC, doses can be safely administered...